ClinicalTrials.gg
CompletedNCT02001987TOSCAUpdated Nov 2, 2018Results posted

A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy

A Phase 3 interventional study of Tocilizumab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 32 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
38th of 110
139 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
80th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 38th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 80th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This two part, multi-center, open-label, single-arm study will evaluate the efficacy and safety of tocilizumab as a monotherapy or in combination with methotrexate or other conventional synthetic disease modifying antirheumatic drugs (csDMARDs) in participants with moderate to severe active rheumatoid arthritis who have an inadequate response or are intolerant to non-biologic csDMARDs and/or biologic therapy.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of active rheumatoid arthritis according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria and receiving outpatient treatment
  • Oral (\</= 10 mg/day prednisone or equivalent), nonsteroidal anti-inflammatory drugs (NSAIDs), and permitted csDMARDs are allowed at a stable dose for at least 4 weeks prior to Baseline
  • At Screening either CRP >/=10 mg/L or ESR >/=20 mm/h and SJC >/=3 (based on 44 joints)
  • Inadequate response (IR) to tumor necrosis factor, abatacept and/or non-biological DMARDs

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline
  • Rheumatic disease other than rheumatoid arthritis; Secondary Sjögren's syndrome with rheumatoid arthritis is permitted
  • Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • Exposure to tocilizumab at any time prior to Baseline
  • Treatment with any agent within 4 weeks (or five half-lives of the investigational drug, whichever was longer) of Screening
  • Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies or any alkylating agents such as chlorambucil, or with total lymphoid irradiation
  • Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline
  • Intraarticular or parenteral within 4 weeks prior to Baseline
  • Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Serious uncontrolled concomitant disease or other significant condition
  • History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal disease
  • Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
  • Any infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening
  • Active tuberculosis requiring treatment within the previous 3 years
  • Positive for or C
  • Primary or secondary immunodeficiency disorder
  • Active cancer, or cancer diagnosed within the previous 10 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised or cured), or breast cancer diagnosed within the previous 20 years
  • History of alcohol, drug, or chemical abuse within 1 year prior to Screening
  • Neuropathies or other conditions that might interfere with pain evaluation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.

    Drug: Tocilizumab · Drug: Methotrexate · Drug: csDMARDs

Interventions

  • Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.

    Also known as: RoActemra, RO4877533

  • Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.

  • DrugcsDMARDs

    csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24

    The DAS28-ESR was derived from assessments of erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and Patient Global Assessment of disease activity (PGA) according to 100-millimeter (mm) Visual Analog Scale (VAS). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in millimeters per hour (mm/h). DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to Week 24 was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in DAS28-ESR at Weeks 2, 4, 8, 12, 16, 20, and 24

    The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  2. Percentage of Participants With DAS28-ESR Low Disease Activity (LDA) and Remission at Week 24

    The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score less than or equal to (\</=) 3.2 indicates LDA, DAS28-ESR score greater than (\>) 3.2 indicates moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 is reported. 95 percent (%) confidence interval (CI) was determined using Clopper-Pearson method.

    Time frame: Week 24

  3. Change From Baseline in DAS28-ESR at Week 24 and at Last Assessment

    The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-millimeter (mm) VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  4. Percentage of Participants With DAS28-ESR LDA and Remission at Week 24 and at Last Assessment

    The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score \</=3.2 indicates LDA, DAS28-ESR score \>3.2 indicates moderate to high disease activity, and DAS28-ESR \<2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 and at last assessment is reported.

    Time frame: Week 24, last assessment (up to Week 76)

  5. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response at Week 24

    The ACR 20, 50, and 70 responses at any time was defined as greater than or equal to (\>/=) 20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per liter \[mg/L\]). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

    Time frame: Baseline, Week 24

  6. Percentage of Participants Achieving ACR20, ACR50, and ACR70 Response at Week 24 and at Last Assessment

    The ACR 20, 50, and 70 responses at any time is defined as \>/=20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/L). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 and at last assessment is reported.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  7. Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28-ESR at Week 24

    The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

    Time frame: Baseline, Week 24

  8. Percentage of Participants With EULAR Response Based on DAS28-ESR at Week 24 and at Last Assessment

    The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 and at last assessment is reported.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  9. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24

    SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg per deciliter (dL). Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  10. Percentage of Participants With SDAI LDA and Remission at Week 24

    SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

    Time frame: Week 24

  11. Change From Baseline in SDAI at Week 24 and at Last Assessment

    SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  12. Percentage of Participants With SDAI LDA and Remission at Week 24 and at Last Assessment

    SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 and at last assessment is reported.

    Time frame: Week 24, last assessment (up to Week 76)

  13. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24

    CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  14. Percentage of Participants With CDAI LDA and Remission at Week 24

    CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

    Time frame: Week 24

  15. Change From Baseline in CDAI at Week 24 and at Last Assessment

    CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  16. Percentage of Participants With CDAI LDA and Remission at Week 24 and at Last Assessment

    CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 and at last assessment is reported.

    Time frame: Week 24, last assessment (up to Week 76)

  17. Change From Baseline in SJC at Weeks 2, 4, 8, 12, 16, 20, and 24

    A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  18. Change From Baseline in SJC at Week 24 and at Last Assessment

    A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  19. Change From Baseline in TJC at Weeks 2, 4, 8, 12, 16, 20, and 24

    A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  20. Change From Baseline in TJC at Week 24 and at Last Assessment

    A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.

    Time frame: Baseline, Week 24, last assessment (up to Week 76)

  21. Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, 8, 12, 16, 20, and 24

    Physician-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in physician-assessed disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24

  22. Change From Baseline in PGA at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

    Participant-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

  23. Change From Baseline in Pain VAS Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

    Participant-assessed pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

  24. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated questions), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The changes from Baseline to any time point were averaged among all participants, where negative changes indicated an increase in fatigue.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

  25. Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Remission at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

    HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI remission (HAQ-DI score \<0.5) at each time point is reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

  26. Percentage of Participants With HAQ-DI Clinically Meaningful Improvement at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

    HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI clinically meaningful improvement (reduction in HAQ-DI score from baseline \>/=0.22) at each time point is reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

  27. Treatment Compliance From Baseline up to Week 24

    Treatment compliance from Baseline up to Week 24 was assessed using following formula: (number of actual injection received / number of theoretical injection which should be received at week 24) \* 100.

    Time frame: Baseline up to Week 24

  28. Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Score at Weeks 12, 24, 28, 40, 52, and 64

    RAID assessed the impact of rheumatoid arthritis on participant's quality of life. It comprised 7 domains: pain, function, fatigue, physical and psychological well-being, sleep disturbance and coping. Each domain was a single question scored from 0 (best) to 10 (worst) on a continuous numerical rating scale (NRS). Each domain also had a specific weight assigned by a participant survey and RAID total score ranged from 0 (best) to 10 (worst). If only 1 domain was missing it was replaced by the mean of the others; otherwise, RAID score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.

    Time frame: Baseline, Weeks 12, 24, 28, 40, 52, and 64

  29. Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID-3) at Weeks 2, 4, 12, 24, 28, 40, 52, and 64

    RAPID-3 is a combined index derived from the Multidimensional Health Assessment Questionnaire that includes physical function score, pain VAS, and PGA VAS. The total RAPID-3 score ranges from 0 to 10 where higher scores represent worse outcomes. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

    Time frame: Baseline, Weeks 2, 4, 12, 24, 28, 40, 52, and 64

  30. Number of Participants With Patient Acceptable Symptom State (PASS) Score

    Participants were asked: "If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) Inacceptable?" The number of participants who responded "acceptable" or "Inacceptable" at each time point is presented.

    Time frame: Baseline, Weeks 24, 52, and last assessment (up to Week 76)

  31. Change From Baseline in Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) Total Score at Weeks 24 and 52

    BRAF-MDQ assessed the overall experience and impact of disease related fatigue, using four dimensions (physical fatigue \[4 items\], living with fatigue \[7 items\], cognitive fatigue \[5 items\], and emotional fatigue \[4 items\]). A total fatigue score (range 0 to 70) was obtained by summing the 20 item scores ranging from 0 to 3, except for item 1 (0-10), item 2 (0-7) and item 3 (0-2). Higher scores reflect greater fatigue. If only 1 domain was missing it was replaced by the mean of the others; otherwise, the total score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.

    Time frame: Baseline, Weeks 24 and 52

  32. Change From Baseline in Bristol Rheumatoid Arthritis Fatigue (BRAF)-NRS Score at Weeks 24 and 52

    BRAF-NRS are 3 standardized NRS (range = 0-10) for disease related fatigue domains (severity of fatigue, fatigue effect, and coping with fatigue). Higher values reflect greater problems for severity/level fatigue and effect fatigue NRS, but lower scores reflect greater problems for copped fatigue NRS.

    Time frame: Baseline, Weeks 24 and 52

  33. Change From Baseline in Medical Outcome Study (MOS) Sleep Questionnaire Score at Weeks 12, 24, 28, 40, 52, and 64

    MOS sleep scale comprised of 6-item with each item score ranged from 0 to 100. The total score was the average of scores sum (range 0-100), with highest values reflecting biggest participant's sleeping problems. If more than 3 items were missing the index was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

    Time frame: Baseline, Weeks 12, 24, 28, 40, 52, and 64

  34. Change From Baseline in Fluctuations of Disease Activity in Rheumatoid Arthritis (FLARE) Questionnaire Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64

    FLARE is a 13-item questionnaire assessed disease flares between two medical consultations. Each item score ranged from 0 (completely untrue) to 10 (absolutely true) on a 6-step scale. The FLARE questionnaire global score (range = 0-10) is a mean score of 11 of the 13 items \[items 6 ('doses of pain killers or anti-inflammatory medication') and 13 ('need for help') not taken into account\], with the highest score corresponding to the highest disease activity. The global score was computed if at least the scores of 6 items were available. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64

  35. Change From Baseline in BioSecure Questionnaire Score at Week 24

    The BioSecure questionnaire comprised of 54-item aimed at evaluating the safety competences of participants (for example, participants' self-care safety skills and socio-demographic characteristics, type of information received, quality of life, and coping style data) treated by biologics for inflammatory arthritis and to determine the factors associated with a lower level of competences.

    Time frame: Baseline, Week 24

  36. Percentage of Participants With Discontinuations of Corticosteroid Dosage During Core Study Period

    Percentage of participants with a discontinuation in corticosteroid dosage during core study period is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  37. Time to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period

    Time to permanent discontinuation in corticosteroid dosage during core study period is reported. Participants who permanently discontinued corticosteroids at any time during core study period were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  38. Time to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period

    Time to first temporary discontinuation in corticosteroid dosage during core study period is reported. Participants who temporarily discontinued corticosteroids at any time during core study period were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  39. Percentage of Participants With Change in Corticosteroid Dosage During Core Study Period

    Percentage of participants with a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  40. Time to Change in Corticosteroid Dosage During Core Study Period

    Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  41. Number of Participants According to Reasons for Change in Corticosteroid Dosage During Core Study Period

    Number of participants according to reasons for a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  42. Percentage of Participants With Discontinuations of Corticosteroid Dosage During Study

    Percentage of participants with a discontinuation in corticosteroid dosage during study is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  43. Time to Permanent Discontinuation of Corticosteroid Dosage During Study

    Time to permanent discontinuation in corticosteroid dosage during study is reported. Participants who permanently discontinued corticosteroids at any time during entire study were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  44. Time to First Temporary Discontinuation of Corticosteroid Dosage During Study

    Time to first temporary discontinuation in corticosteroid dosage during study is reported. Participants who temporarily discontinued corticosteroids at any time during entire study were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  45. Percentage of Participants With Change in Corticosteroid Dosage During Study

    Percentage of participants with a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  46. Time to Change in Corticosteroid Dosage During Study

    Time to first change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  47. Number of Participants According to Reasons for Change in Corticosteroid Dosage During Study

    Number of participants according to reasons for a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  48. Number of Participants According to Reasons for Changes in csDMARDs Treatment During Core Study Period

    Number of participants according to reasons for changes in csDMARDs treatment during core study period is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to intravenous (IV)/ intramuscular (IM)/ SC. Participants with a change in csDMARDs treatment during core study period were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)

  49. Number of Participants According to Reasons for Changes in csDMARDs Treatment During Study

    Number of participants according to reasons for changes in csDMARDs treatment during study is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to IV/IM/SC. Participants with a change in csDMARDs treatment during entire study were only included in the analysis.

    Time frame: Screening up to 8 weeks after last dose (overall up to 88 weeks)

  50. Change From Baseline in Synovitis Ultrasound B-Mode Score at Week 24

    Synovitis was assessed by ultrasonographic evaluation (B-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

    Time frame: Baseline, Weeks 24

  51. Change From Baseline in Synovitis Ultrasound Power-Doppler Mode Score at Week 24

    Synovitis was assessed by ultrasonographic evaluation (Power-Doppler-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

    Time frame: Baseline, Weeks 24

  52. Percentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab

    Percentage of participants with a positive response to anti-therapeutic antibodies against tocilizumab by confirmatory assays at any time during the study is reported.

    Time frame: Baseline up to 8 weeks after last study drug administration (up to Week 84)

07

Results

Posted Nov 2, 2018

Participant flow

A total of 183 participants were screened; 139 participants were eligible for the study and assigned to study treatment.

Core Study Period (24 Weeks)
Participant flow — Core Study Period (24 Weeks)
MilestoneTCZ - All Participants
Started139
Completed116
Not completed23
Withdrew: Adverse event9
Withdrew: Death1
Withdrew: Non-serious hypersensitivity reaction2
Withdrew: Physician decision1
Withdrew: Withdrawal by subject4
Withdrew: Protocol violation3
Withdrew: Lack of efficacy3
LTE Period (52 Weeks)
Participant flow — LTE Period (52 Weeks)
MilestoneTCZ - All Participants
Started116
Completed107
Not completed9
Withdrew: Lost to follow-up2
Withdrew: Physician decision2
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy1
Withdrew: Other3

Outcome measures

PrimaryChange From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24

The DAS28-ESR was derived from assessments of erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), and Patient Global Assessment of disease activity (PGA) according to 100-millimeter (mm) Visual Analog Scale (VAS). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in millimeters per hour (mm/h). DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to Week 24 was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score Based on 28-joints Count and Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 24
units on a scaleTCZ - All Participants - Core Study Period
Baseline5.80 ± 1.14
Change at Week 24-3.07 ± 1.52
SecondaryChange From Baseline in DAS28-ESR at Weeks 2, 4, 8, 12, 16, 20, and 24

The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Weeks 2, 4, 8, 12, 16, 20, and 24
units on a scaleTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Baseline6.08 ± 1.215.67 ± 1.10
Change at Week 2-1.19 ± 1.05-1.41 ± 1.03
Change at Week 4-2.16 ± 1.17-2.21 ± 1.14
Change at Week 8-2.70 ± 1.40-2.74 ± 1.36
Change at Week 12-3.16 ± 1.54-3.02 ± 1.33
Change at Week 16-3.20 ± 1.59-3.08 ± 1.29
Change at Week 20-3.27 ± 1.35-3.21 ± 1.43
Change at Week 24-3.01 ± 1.62-3.10 ± 1.48
SecondaryPercentage of Participants With DAS28-ESR Low Disease Activity (LDA) and Remission at Week 24

The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score less than or equal to (\</=) 3.2 indicates LDA, DAS28-ESR score greater than (\>) 3.2 indicates moderate to high disease activity, and DAS28-ESR less than (\<) 2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 is reported. 95 percent (%) confidence interval (CI) was determined using Clopper-Pearson method.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-ESR Low Disease Activity (LDA) and Remission at Week 24
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
LDA67.4 (51.46 to 80.92)70.8 (60.67 to 79.67)
Remission41.9 (27.01 to 57.87)55.2 (44.71 to 65.37)
SecondaryChange From Baseline in DAS28-ESR at Week 24 and at Last Assessment

The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-millimeter (mm) VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 24 and at Last Assessment
units on a scaleTCZ - All Participants
Baseline5.90 ± 1.26
Change at Week 24-3.30 ± 1.44
Change at Last Assessment-3.41 ± 1.47
SecondaryPercentage of Participants With DAS28-ESR LDA and Remission at Week 24 and at Last Assessment

The DAS28-ESR was derived from assessments of ESR, TJC, SJC, and PGA according to 100-mm VAS. DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. ESR was measured in mm/h. DAS28-ESR scores could range from 0 to 10, where higher scores represented higher disease activity. DAS28-ESR score \</=3.2 indicates LDA, DAS28-ESR score \>3.2 indicates moderate to high disease activity, and DAS28-ESR \<2.6 indicates remission. Percentage of participants with DAS28-ESR LDA and remission at Week 24 and at last assessment is reported.

Time frame:
Week 24, last assessment (up to Week 76)
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-ESR LDA and Remission at Week 24 and at Last Assessment
percentage of participantsTCZ - All Participants
Week 24, LDA71.9
Week 24, Remission54.7
Last Assessment, LDA71.9
Last Assessment, Remission53.1
SecondaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response at Week 24

The ACR 20, 50, and 70 responses at any time was defined as greater than or equal to (\>/=) 20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via a Health Assessment Questionnaire-Disability Index (HAQ-DI), and 5) Acute phase reactant (ESR in mm/h or C-Reactive Protein \[CRP\] in milligrams per liter \[mg/L\]). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response at Week 24
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
ACR2069.7 (51.29 to 84.41)73.8 (63.07 to 82.80)
ACR5054.5 (36.35 to 71.89)52.4 (41.19 to 63.40)
ACR7033.3 (17.96 to 51.83)28.6 (19.24 to 39.47)
SecondaryPercentage of Participants Achieving ACR20, ACR50, and ACR70 Response at Week 24 and at Last Assessment

The ACR 20, 50, and 70 responses at any time is defined as \>/=20%, 50%, and 70% improvement compared to baseline in TJC (assessed on 68 joints) and SJC (assessed on 66 joints); and 20%, 50%, 70% improvement compared to baseline in 3 of the following 5 criteria, respectively: 1) PGA according to 100-mm VAS, 2) Physician's global assessment of disease activity according to 100-mm VAS, 3) participant's global assessment of pain according to 100-mm VAS, 4) Participant's assessment of functional ability via HAQ-DI, and 5) Acute phase reactant (ESR in mm/h or CRP in mg/L). Percentage of participants with ACR 20, 50, and 70 responses at Week 24 and at last assessment is reported.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20, ACR50, and ACR70 Response at Week 24 and at Last Assessment
percentage of participantsTCZ - All Participants
Week 24, ACR2076.6
Week 24, ACR5051.6
Week 24, ACR7035.9
Last Assessment, ACR2076.6
Last Assessment, ACR5056.3
Last Assessment, ACR7037.5
SecondaryPercentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28-ESR at Week 24

The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28-ESR at Week 24
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Good Response58.1 (42.13 to 72.99)60.4 (49.92 to 70.25)
Moderate Response14.0 (5.30 to 27.93)19.8 (12.36 to 29.17)
No Response27.9 (15.33 to 43.67)19.8 (12.36 to 29.17)
SecondaryPercentage of Participants With EULAR Response Based on DAS28-ESR at Week 24 and at Last Assessment

The DAS28-ESR-based EULAR response criteria were used to measure individual response as 'Good', 'Moderate', and 'No Response', depending upon DAS28-ESR absolute scores at Week 24 and the DAS28-ESR reduction from Baseline to Week 24. Good Response: change from baseline \>1.2 with DAS28-ESR score \</=3.2; Moderate Response: change from baseline \>1.2 with DAS28-ESR score \>3.2 to \</=5.1 or change from baseline \>0.6 to \</=1.2 with DAS28-ESR score \</=5.1; No Response: change from baseline \</=0.6 or change from baseline \>0.6 and \</=1.2 with DAS28-ESR score \>5.1. Percentage of participants with EULAR responses at Week 24 and at last assessment is reported.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Number · percentage of participants
Percentage of Participants With EULAR Response Based on DAS28-ESR at Week 24 and at Last Assessment
percentage of participantsTCZ - All Participants
Week 24, Good Response68.8
Week 24, Moderate Response26.6
Week 24, No Response4.7
Last Assessment, Good Response65.6
Last Assessment, Moderate Response31.3
Last Assessment, No Response3.1
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24

SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg per deciliter (dL). Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24
units on a scaleTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Baseline35.42 ± 12.6131.47 ± 11.77
Change at Week 2-8.54 ± 10.67-9.20 ± 9.37
Change at Week 4-14.23 ± 10.76-14.62 ± 11.33
Change at Week 8-20.20 ± 13.22-17.47 ± 12.47
Change at Week 12-23.09 ± 13.82-20.33 ± 12.97
Change at Week 16-24.31 ± 15.14-21.39 ± 12.66
Change at Week 20-24.41 ± 15.28-21.93 ± 13.35
Change at Week 24-22.45 ± 14.48-20.31 ± 13.34
SecondaryPercentage of Participants With SDAI LDA and Remission at Week 24

SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With SDAI LDA and Remission at Week 24
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
LDA46.5 (31.18 to 62.35)59.4 (48.87 to 69.29)
Remission18.6 (8.39 to 33.40)19.8 (12.36 to 29.17)
SecondaryChange From Baseline in SDAI at Week 24 and at Last Assessment

SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Mean · units on a scale
Change From Baseline in SDAI at Week 24 and at Last Assessment
units on a scaleTCZ - All Participants
Change at Week 24-23.29 ± 13.81
Change at Last Assessment-24.36 ± 12.61
SecondaryPercentage of Participants With SDAI LDA and Remission at Week 24 and at Last Assessment

SDAI is a numerical sum of 5 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS and CRP in mg/dL. Higher scores indicate greater affection due to disease activity. SDAI total score = 0-86. SDAI \</=3.3 indicates disease remission, \</=11 indicates LDA, \</=26 indicates moderate disease activity, and \>26 indicates high disease activity. Percentage of participants with SDAI LDA and remission at Week 24 and at last assessment is reported.

Time frame:
Week 24, last assessment (up to Week 76)
Reported as:
Number · percentage of participants
Percentage of Participants With SDAI LDA and Remission at Week 24 and at Last Assessment
percentage of participantsTCZ - All Participants
Week 24, LDA57.8
Week 24, Remission20.3
Last Assessment, LDA64.1
Last Assessment, Remission25.0
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24

CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, and 24
units on a scaleTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Baseline32.17 ± 11.1129.34 ± 11.05
Change at Week 2-5.57 ± 9.69-7.15 ± 8.87
Change at Week 4-11.17 ± 10.14-12.65 ± 10.97
Change at Week 8-17.32 ± 12.00-15.75 ± 11.62
Change at Week 12-20.25 ± 12.50-18.17 ± 12.20
Change at Week 16-20.24 ± 14.13-19.25 ± 11.88
Change at Week 20-21.27 ± 13.58-19.29 ± 12.82
Change at Week 24-19.45 ± 13.34-18.40 ± 12.78
SecondaryPercentage of Participants With CDAI LDA and Remission at Week 24

CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 is reported. 95% CI was determined using Clopper-Pearson method.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With CDAI LDA and Remission at Week 24
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
LDA44.2 (29.08 to 60.12)60.4 (49.92 to 70.25)
Remission16.3 (6.81 to 30.70)16.7 (9.84 to 25.65)
SecondaryChange From Baseline in CDAI at Week 24 and at Last Assessment

CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Mean · units on a scale
Change From Baseline in CDAI at Week 24 and at Last Assessment
units on a scaleTCZ - All Participants
Change at Week 24-20.85 ± 13.06
Change at Last Assessment-21.74 ± 12.06
SecondaryPercentage of Participants With CDAI LDA and Remission at Week 24 and at Last Assessment

CDAI is a numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PGA and Physician's global assessment of disease activity according to 100-mm VAS. Higher scores represent greater affection due to disease activity. CDAI total score = 0-76. CDAI score \</=2.8 indicates disease remission, \</=10 indicates LDA, \</=22 indicates moderate disease activity, and \>22 indicates high disease activity. Percentage of participants with CDAI LDA and remission at Week 24 and at last assessment is reported.

Time frame:
Week 24, last assessment (up to Week 76)
Reported as:
Number · percentage of participants
Percentage of Participants With CDAI LDA and Remission at Week 24 and at Last Assessment
percentage of participantsTCZ - All Participants
Week 24, LDA57.8
Week 24, Remission17.2
Last Assessment, LDA60.9
Last Assessment, Remission23.4
SecondaryChange From Baseline in SJC at Weeks 2, 4, 8, 12, 16, 20, and 24

A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Median · swollen joints
Change From Baseline in SJC at Weeks 2, 4, 8, 12, 16, 20, and 24
swollen jointsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Baseline6.0 (0.0 to 24.0)7.0 (0.0 to 23.0)
Change at Week 2-1.0 (-9.0 to 14.0)-2.0 (-13.0 to 8.0)
Change at Week 4-3.0 (-8.0 to 4.0)-3.0 (-18.0 to 5.0)
Change at Week 8-3.5 (-18.0 to 6.0)-4.0 (-17.0 to 3.0)
Change at Week 12-4.0 (-22.0 to 3.0)-5.0 (-23.0 to 2.0)
Change at Week 16-5.0 (-22.0 to 6.0)-5.0 (-23.0 to 2.0)
Change at Week 20-4.0 (-21.0 to 3.0)-5.0 (-22.0 to 4.0)
Change at Week 24-5.0 (-21.0 to 14.0)-5.0 (-23.0 to 2.0)
SecondaryChange From Baseline in SJC at Week 24 and at Last Assessment

A total of 28 joints were assessed for swelling. The number of swollen joints at could range from 0 to 28, where higher values represented more swollen joints. The change from Baseline to any time point was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Median · swollen joints
Change From Baseline in SJC at Week 24 and at Last Assessment
swollen jointsTCZ - All Participants
Change at Week 24-6.0 (-23.0 to 2.0)
Change at Last Assessment-6.5 (-22.0 to 5.0)
SecondaryChange From Baseline in TJC at Weeks 2, 4, 8, 12, 16, 20, and 24

A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Median · tender joints
Change From Baseline in TJC at Weeks 2, 4, 8, 12, 16, 20, and 24
tender jointsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Baseline12.0 (0.0 to 28.0)8.0 (0.0 to 27.0)
Change at Week 2-1.0 (-13.0 to 12.0)-2.0 (-18.0 to 12.0)
Change at Week 4-2.5 (-17.0 to 4.0)-3.0 (-20.0 to 10.0)
Change at Week 8-6.5 (-19.0 to 12.0)-5.0 (-21.0 to 8.0)
Change at Week 12-8.0 (-23.0 to 3.0)-5.0 (-20.0 to 17.0)
Change at Week 16-8.0 (-24.0 to 8.0)-5.5 (-23.0 to 4.0)
Change at Week 20-8.0 (-27.0 to 5.0)-5.0 (-25.0 to 12.0)
Change at Week 24-8.0 (-27.0 to 12.0)-5.0 (-27.0 to 15.0)
SecondaryChange From Baseline in TJC at Week 24 and at Last Assessment

A total of 28 joints were assessed for tenderness. The number of tender joints at could range from 0 to 28, where higher values represented more tender joints. The change from Baseline to any time points was averaged among all participants, where negative changes indicated an improvement in disease activity.

Time frame:
Baseline, Week 24, last assessment (up to Week 76)
Reported as:
Median · tender joints
Change From Baseline in TJC at Week 24 and at Last Assessment
tender jointsTCZ - All Participants
Change at Week 24-6.5 (-27.0 to 15.0)
Change at Last Assessment-6.0 (-27.0 to 9.0)
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, 8, 12, 16, 20, and 24

Physician-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in physician-assessed disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment of Disease Activity at Weeks 2, 4, 8, 12, 16, 20, and 24
mmTCZ - All Participants
Baseline62.08 ± 17.68
Change at Week 2-11.38 ± 15.91
Change at Week 4-22.10 ± 20.25
Change at Week 8-29.67 ± 23.33
Change at Week 12-35.25 ± 22.03
Change at Week 16-35.69 ± 23.33
Change at Week 20-37.80 ± 21.80
Change at Week 24-34.98 ± 22.43
SecondaryChange From Baseline in PGA at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

Participant-assessed disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of disease activity (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Reported as:
Mean · mm
Change From Baseline in PGA at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
mmTCZ - All Participants
Baseline59.88 ± 24.14
Change at Week 2-8.11 ± 21.64
Change at Week 4-17.19 ± 25.71
Change at Week 8-24.49 ± 29.94
Change at Week 12-29.62 ± 29.84
Change at Week 16-31.61 ± 28.89
Change at Week 20-31.80 ± 31.16
Change at Week 24-33.79 ± 31.19
Change at Week 28-37.90 ± 29.87
Change at Week 32-33.96 ± 32.19
Change at Week 36-34.10 ± 30.05
Change at Week 40-37.74 ± 28.63
Change at Week 44-36.55 ± 26.27
Change at Week 48-37.63 ± 26.07
Change at Week 52-37.50 ± 33.25
Change at Week 56-41.00 ± 41.91
Change at Week 60-46.00 ± 49.50
Change at Week 64-42.50 ± 53.03
SecondaryChange From Baseline in Pain VAS Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

Participant-assessed pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm=none; 100 mm=very severe). The change from Baseline to any time point was averaged among all participants, where negative change indicated a decrease in participant-assessed pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Reported as:
Mean · mm
Change From Baseline in Pain VAS Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
mmTCZ - All Participants
Baseline57.57 ± 26.78
Change at Week 2-7.50 ± 22.78
Change at Week 4-15.28 ± 29.76
Change at Week 8-22.58 ± 32.15
Change at Week 12-28.29 ± 32.04
Change at Week 16-29.50 ± 29.98
Change at Week 20-30.55 ± 29.98
Change at Week 24-31.85 ± 30.21
Change at Week 28-33.29 ± 31.84
Change at Week 32-32.67 ± 30.98
Change at Week 36-34.51 ± 30.03
Change at Week 40-34.36 ± 31.07
Change at Week 44-32.30 ± 27.10
Change at Week 48-35.56 ± 26.27
Change at Week 52-36.42 ± 32.77
Change at Week 56-39.50 ± 34.67
Change at Week 60-42.00 ± 43.84
Change at Week 64-40.00 ± 43.84
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated questions), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The changes from Baseline to any time point were averaged among all participants, where negative changes indicated an increase in fatigue.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
units on a scaleTCZ - All Participants
Baseline25.44 ± 11.97
Change at Week 23.71 ± 8.20
Change at Week 46.08 ± 9.74
Change at Week 87.98 ± 12.36
Change at Week 129.43 ± 11.54
Change at Week 169.19 ± 11.89
Change at Week 208.84 ± 12.68
Change at Week 249.26 ± 13.08
Change at Week 2811.54 ± 12.18
Change at Week 329.87 ± 12.25
Change at Week 368.63 ± 12.17
Change at Week 4010.41 ± 11.73
Change at Week 4410.30 ± 12.37
Change at Week 4811.50 ± 9.14
Change at Week 5212.25 ± 10.70
Change at Week 5614.83 ± 7.36
Change at Week 6017.00 ± 7.07
Change at Week 6420.00 ± 7.07
SecondaryPercentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Remission at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI remission (HAQ-DI score \<0.5) at each time point is reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Reported as:
Number · percentage of participants
Percentage of Participants With Health Assessment Questionnaire-Disability Index (HAQ-DI) Remission at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
percentage of participantsTCZ - All Participants
Baseline6.0
Week 28.4
Week 412.6
Week 823.3
Week 1231.7
Week 1635.9
Week 2031.3
Week 2430.3
Week 2837.3
Week 3232.1
Week 3625.0
Week 4030.4
Week 4430.0
Week 4825.0
Week 5233.3
Week 5633.3
Week 6050.0
Week 6450.0
SecondaryPercentage of Participants With HAQ-DI Clinically Meaningful Improvement at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64

HAQ-DI assessed 20 items in 8 functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score (range = 0-3) was calculated as an average of all item scores. Percentage of participants with HAQ-DI clinically meaningful improvement (reduction in HAQ-DI score from baseline \>/=0.22) at each time point is reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
Reported as:
Number · percentage of participants
Percentage of Participants With HAQ-DI Clinically Meaningful Improvement at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, and 64
percentage of participantsTCZ - All Participants
Week 242.5
Week 455.3
Week 862.1
Week 1271.6
Week 1675.0
Week 2067.6
Week 2473.6
Week 2876.8
Week 3272.0
Week 3664.9
Week 4073.9
Week 4465.0
Week 4862.5
Week 5250.0
Week 5666.7
Week 60100.0
Week 6450.0
SecondaryTreatment Compliance From Baseline up to Week 24

Treatment compliance from Baseline up to Week 24 was assessed using following formula: (number of actual injection received / number of theoretical injection which should be received at week 24) \* 100.

Time frame:
Baseline up to Week 24
Reported as:
Mean · percentage of injections
Treatment Compliance From Baseline up to Week 24
percentage of injectionsTCZ - All Participants - Core Study Period
Treatment Compliance From Baseline up to Week 2491.19 ± 15.54
SecondaryChange From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Score at Weeks 12, 24, 28, 40, 52, and 64

RAID assessed the impact of rheumatoid arthritis on participant's quality of life. It comprised 7 domains: pain, function, fatigue, physical and psychological well-being, sleep disturbance and coping. Each domain was a single question scored from 0 (best) to 10 (worst) on a continuous numerical rating scale (NRS). Each domain also had a specific weight assigned by a participant survey and RAID total score ranged from 0 (best) to 10 (worst). If only 1 domain was missing it was replaced by the mean of the others; otherwise, RAID score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.

Time frame:
Baseline, Weeks 12, 24, 28, 40, 52, and 64
Reported as:
Mean · units on a scale
Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Score at Weeks 12, 24, 28, 40, 52, and 64
units on a scaleTCZ - All Participants
Baseline5.94 ± 2.27
Change at Week 12-2.74 ± 2.39
Change at Week 24-2.94 ± 2.65
Change at Week 28-2.99 ± 2.50
Change at Week 40-3.21 ± 2.46
Change at Week 52-3.27 ± 2.52
Change at Week 64-5.59 ± 0.74
SecondaryChange From Baseline in Routine Assessment of Patient Index Data 3 (RAPID-3) at Weeks 2, 4, 12, 24, 28, 40, 52, and 64

RAPID-3 is a combined index derived from the Multidimensional Health Assessment Questionnaire that includes physical function score, pain VAS, and PGA VAS. The total RAPID-3 score ranges from 0 to 10 where higher scores represent worse outcomes. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

Time frame:
Baseline, Weeks 2, 4, 12, 24, 28, 40, 52, and 64
Reported as:
Mean · units on a scale
Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID-3) at Weeks 2, 4, 12, 24, 28, 40, 52, and 64
units on a scaleTCZ - All Participants
Baseline15.41 ± 6.54
Change at Week 2-1.72 ± 4.96
Change at Week 4-4.18 ± 6.08
Change at Week 12-7.07 ± 7.01
Change at Week 24-7.68 ± 7.16
Change at Week 28-8.16 ± 6.81
Change at Week 40-8.86 ± 6.70
Change at Week 52-8.91 ± 7.79
Change at Week 64-9.00 ± 9.90
SecondaryNumber of Participants With Patient Acceptable Symptom State (PASS) Score

Participants were asked: "If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) Inacceptable?" The number of participants who responded "acceptable" or "Inacceptable" at each time point is presented.

Time frame:
Baseline, Weeks 24, 52, and last assessment (up to Week 76)
Reported as:
Count of participants · Participants
Number of Participants With Patient Acceptable Symptom State (PASS) Score
ParticipantsTCZ - All Participants
Baseline, Acceptable31
Baseline, Inacceptable101
Week 24, Acceptable78
Week 24, Incceptable27
Week 52, Acceptable8
Week 52, Inacceptable3
Last Assessment, Acceptable83
Last Assessment, Inacceptable35
SecondaryChange From Baseline in Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) Total Score at Weeks 24 and 52

BRAF-MDQ assessed the overall experience and impact of disease related fatigue, using four dimensions (physical fatigue \[4 items\], living with fatigue \[7 items\], cognitive fatigue \[5 items\], and emotional fatigue \[4 items\]). A total fatigue score (range 0 to 70) was obtained by summing the 20 item scores ranging from 0 to 3, except for item 1 (0-10), item 2 (0-7) and item 3 (0-2). Higher scores reflect greater fatigue. If only 1 domain was missing it was replaced by the mean of the others; otherwise, the total score was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better quality of life.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ) Total Score at Weeks 24 and 52
units on a scaleTCZ - All Participants
Baseline35.50 ± 18.93
Change at Week 24-13.18 ± 18.56
Change at Week 52-20.09 ± 19.02
SecondaryChange From Baseline in Bristol Rheumatoid Arthritis Fatigue (BRAF)-NRS Score at Weeks 24 and 52

BRAF-NRS are 3 standardized NRS (range = 0-10) for disease related fatigue domains (severity of fatigue, fatigue effect, and coping with fatigue). Higher values reflect greater problems for severity/level fatigue and effect fatigue NRS, but lower scores reflect greater problems for copped fatigue NRS.

Time frame:
Baseline, Weeks 24 and 52
Reported as:
Mean · units on a scale
Change From Baseline in Bristol Rheumatoid Arthritis Fatigue (BRAF)-NRS Score at Weeks 24 and 52
units on a scaleTCZ - All Participants
Baseline, Level Fatigue NRS6.14 ± 2.56
Baseline, Effect Fatigue NRS5.87 ± 2.75
Baseline, Copped Fatigue NRS5.48 ± 2.52
Change at Week 24, Level Fatigue NRS-2.41 ± 2.90
Change at Week 24, Effect Fatigue NRS-2.44 ± 2.90
Change at Week 24, Copped Fatigue NRS-0.47 ± 3.91
Change at Week 52, Level Fatigue NRS-3.75 ± 2.93
Change at Week 52, Effect Fatigue NRS-3.83 ± 2.86
Change at Week 52, Copped Fatigue NRS-1.33 ± 2.84
SecondaryChange From Baseline in Medical Outcome Study (MOS) Sleep Questionnaire Score at Weeks 12, 24, 28, 40, 52, and 64

MOS sleep scale comprised of 6-item with each item score ranged from 0 to 100. The total score was the average of scores sum (range 0-100), with highest values reflecting biggest participant's sleeping problems. If more than 3 items were missing the index was not calculated. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

Time frame:
Baseline, Weeks 12, 24, 28, 40, 52, and 64
Reported as:
Mean · units on a scale
Change From Baseline in Medical Outcome Study (MOS) Sleep Questionnaire Score at Weeks 12, 24, 28, 40, 52, and 64
units on a scaleTCZ - All Participants
Baseline47.09 ± 21.66
Change at Week 12-7.21 ± 18.85
Change at Week 24-5.44 ± 19.83
Change at Week 28-8.48 ± 15.04
Change at Week 40-5.56 ± 14.45
Change at Week 52-8.33 ± 18.11
Change at Week 64-27.08 ± 2.95
SecondaryChange From Baseline in Fluctuations of Disease Activity in Rheumatoid Arthritis (FLARE) Questionnaire Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64

FLARE is a 13-item questionnaire assessed disease flares between two medical consultations. Each item score ranged from 0 (completely untrue) to 10 (absolutely true) on a 6-step scale. The FLARE questionnaire global score (range = 0-10) is a mean score of 11 of the 13 items \[items 6 ('doses of pain killers or anti-inflammatory medication') and 13 ('need for help') not taken into account\], with the highest score corresponding to the highest disease activity. The global score was computed if at least the scores of 6 items were available. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64
Reported as:
Mean · units on a scale
Change From Baseline in Fluctuations of Disease Activity in Rheumatoid Arthritis (FLARE) Questionnaire Score at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 40, 52, and 64
units on a scaleTCZ - All Participants
Baseline5.61 ± 2.77
Change at Week 2-1.35 ± 2.41
Change at Week 4-2.38 ± 2.64
Change at Week 8-2.94 ± 3.18
Change at Week 12-3.41 ± 2.62
Change at Week 16-3.10 ± 2.89
Change at Week 20-3.30 ± 2.93
Change at Week 24-3.41 ± 2.75
Change at Week 28-3.31 ± 2.54
Change at Week 40-3.44 ± 2.01
Change at Week 52-4.16 ± 1.99
Change at Week 64-7.55 ± 1.54
SecondaryChange From Baseline in BioSecure Questionnaire Score at Week 24

The BioSecure questionnaire comprised of 54-item aimed at evaluating the safety competences of participants (for example, participants' self-care safety skills and socio-demographic characteristics, type of information received, quality of life, and coping style data) treated by biologics for inflammatory arthritis and to determine the factors associated with a lower level of competences.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Discontinuations of Corticosteroid Dosage During Core Study Period

Percentage of participants with a discontinuation in corticosteroid dosage during core study period is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinuations of Corticosteroid Dosage During Core Study Period
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Permanent Discontinuation8.37.3
Temporary Discontinuation16.77.3
SecondaryTime to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period

Time to permanent discontinuation in corticosteroid dosage during core study period is reported. Participants who permanently discontinued corticosteroids at any time during core study period were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Median · days
Time to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period
daysTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Time to Permanent Discontinuation of Corticosteroid Dosage During Core Study Period24 (1 to 46)96 (24 to 114)
SecondaryTime to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period

Time to first temporary discontinuation in corticosteroid dosage during core study period is reported. Participants who temporarily discontinued corticosteroids at any time during core study period were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Median · days
Time to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period
daysTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Time to First Temporary Discontinuation of Corticosteroid Dosage During Core Study Period50 (1 to 156)105 (76 to 138)
SecondaryPercentage of Participants With Change in Corticosteroid Dosage During Core Study Period

Percentage of participants with a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Change in Corticosteroid Dosage During Core Study Period
percentage of participantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Initiation/ Increase0.03.1
Decrease14.09.4
SecondaryTime to Change in Corticosteroid Dosage During Core Study Period

Time to first change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Median · days
Time to Change in Corticosteroid Dosage During Core Study Period
daysTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Initiation/ Increase—38 (23 to 50)
Decrease98 (1 to 239)107 (25 to 225)
SecondaryNumber of Participants According to Reasons for Change in Corticosteroid Dosage During Core Study Period

Number of participants according to reasons for a change in corticosteroid dosage during core study period compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during core study period were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants According to Reasons for Change in Corticosteroid Dosage During Core Study Period
ParticipantsTCZ MONO - Core Study PeriodTCZ COMBO - Core Study Period
Initiation/ Increase, Lack of Efficacy01
Initiation/ Increase, End of Treatment Planned01
Initiation/ Increase, Other Reason01
Decrease, Adverse Event10
Decrease, Lack of Efficacy01
Decrease, End of Treatment Planned23
Decrease, Other Reason35
SecondaryPercentage of Participants With Discontinuations of Corticosteroid Dosage During Study

Percentage of participants with a discontinuation in corticosteroid dosage during study is reported. The discontinuations were categorized as either permanent or temporary. Participants with temporary discontinuation first followed by permanent discontinuation were counted in both categories. Participants who were receiving corticosteroids at Baseline were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinuations of Corticosteroid Dosage During Study
percentage of participantsTCZ - All Participants
Permanent Discontinuation10.0
Temporary Discontinuation15.0
SecondaryTime to Permanent Discontinuation of Corticosteroid Dosage During Study

Time to permanent discontinuation in corticosteroid dosage during study is reported. Participants who permanently discontinued corticosteroids at any time during entire study were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Median · days
Time to Permanent Discontinuation of Corticosteroid Dosage During Study
daysTCZ - All Participants
Time to Permanent Discontinuation of Corticosteroid Dosage During Study202 (107 to 328)
SecondaryTime to First Temporary Discontinuation of Corticosteroid Dosage During Study

Time to first temporary discontinuation in corticosteroid dosage during study is reported. Participants who temporarily discontinued corticosteroids at any time during entire study were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Median · days
Time to First Temporary Discontinuation of Corticosteroid Dosage During Study
daysTCZ - All Participants
Time to First Temporary Discontinuation of Corticosteroid Dosage During Study147 (96 to 290)
SecondaryPercentage of Participants With Change in Corticosteroid Dosage During Study

Percentage of participants with a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Change in Corticosteroid Dosage During Study
percentage of participantsTCZ - All Participants
Initiation/ Increase3.1
Decrease21.9
SecondaryTime to Change in Corticosteroid Dosage During Study

Time to first change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Median · days
Time to Change in Corticosteroid Dosage During Study
daysTCZ - All Participants
Initiation/ Increase44 (38 to 50)
Decrease210 (96 to 428)
SecondaryNumber of Participants According to Reasons for Change in Corticosteroid Dosage During Study

Number of participants according to reasons for a change in corticosteroid dosage during study compared to Baseline is reported. The change included either an initiation/ increase (\>+5mg/day prednisone or equivalent) of corticosteroid dosage or a decrease (\</=-5mg/day prednisone or equivalent) of corticosteroid dosage. Participants with a change in corticosteroid dosage during entire study were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Count of participants · Participants
Number of Participants According to Reasons for Change in Corticosteroid Dosage During Study
ParticipantsTCZ - All Participants
Initiation/ Increase, Lack of Efficacy1
Initiation/ Increase, Other Reason1
Decrease, Lack of Efficacy1
Decrease, End of Treatment Planned4
Decrease, Other Reason9
SecondaryNumber of Participants According to Reasons for Changes in csDMARDs Treatment During Core Study Period

Number of participants according to reasons for changes in csDMARDs treatment during core study period is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to intravenous (IV)/ intramuscular (IM)/ SC. Participants with a change in csDMARDs treatment during core study period were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose in core study period (overall up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants According to Reasons for Changes in csDMARDs Treatment During Core Study Period
ParticipantsTCZ - All Participants - Core Study Period
Adverse Event19
End of Treatment Planned2
Lack of Efficacy1
Poor Treatment Compliance1
Other Reason6
SecondaryNumber of Participants According to Reasons for Changes in csDMARDs Treatment During Study

Number of participants according to reasons for changes in csDMARDs treatment during study is reported. The changes included Increase of dose (the dose increase had to be greater than the highest dose received within the 4 weeks on or before baseline); Addition of another csDMARD (without suppression of the first one); Switch (add and suppression) of a csDMARD for another reason than intolerance to the csDMARD suppressed; Modification of the administration route of MTX (with increase or maintenance of the dose): per oral route to IV/IM/SC. Participants with a change in csDMARDs treatment during entire study were only included in the analysis.

Time frame:
Screening up to 8 weeks after last dose (overall up to 88 weeks)
Reported as:
Count of participants · Participants
Number of Participants According to Reasons for Changes in csDMARDs Treatment During Study
ParticipantsTCZ - All Participants
Adverse Event5
End of Treatment Planned1
Lack of Efficacy2
Poor Treatment Compliance1
Other Reason3
SecondaryChange From Baseline in Synovitis Ultrasound B-Mode Score at Week 24

Synovitis was assessed by ultrasonographic evaluation (B-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

Time frame:
Baseline, Weeks 24
Reported as:
Median · units on a scale
Change From Baseline in Synovitis Ultrasound B-Mode Score at Week 24
units on a scaleTCZ - All Participants
Baseline14.0 (2.0 to 37.0)
Change at Week 24-8.0 (-29.0 to 8.0)
SecondaryChange From Baseline in Synovitis Ultrasound Power-Doppler Mode Score at Week 24

Synovitis was assessed by ultrasonographic evaluation (Power-Doppler-mode ultrasound) and scored from "0" to "3" for each 7 paired joints (wrists on both sides, 2nd and 3rd metacarpo-phalangeal \[MCP 2/3\] on both sides, 2nd and 3rd proximal inter-phalangeal \[PIP 2/3\] on both sides, 2nd and 5th metatarsophalangeal \[MTP 2/5\] on both sides). Synovitis total score was calculated by adding the sum of scores for each joint for a total score ranging from 0 to 42. A score of 0 indicated no damage and a score of 42 indicated most severe damage. The changes from Baseline to any time point were averaged among all participants, where negative changes indicated better outcome.

Time frame:
Baseline, Weeks 24
Reported as:
Median · units on a scale
Change From Baseline in Synovitis Ultrasound Power-Doppler Mode Score at Week 24
units on a scaleTCZ - All Participants
Baseline5.0 (0.0 to 26.0)
Change at Week 24-4.0 (-21.0 to 11.0)
SecondaryPercentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab

Percentage of participants with a positive response to anti-therapeutic antibodies against tocilizumab by confirmatory assays at any time during the study is reported.

Time frame:
Baseline up to 8 weeks after last study drug administration (up to Week 84)
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab
percentage of participantsTCZ - All Participants
Percentage of Participants With Anti-Therapeutic Antibodies to Tocilizumab3.6

Adverse events

Collected over Baseline up to 8 weeks after last study drug administration (up to Week 84). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TCZ MONO - All Participants—5/43 (11.6%)28/43 (65.1%)
TCZ COMBO - All Participants—11/96 (11.5%)65/96 (67.7%)
TCZ - All Participants—16/139 (11.5%)93/139 (66.9%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTCZ MONO - All ParticipantsTCZ COMBO - All ParticipantsTCZ - All Participants
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/431/963/139
Abdominal painGastrointestinal disorders1/430/961/139
DiarrhoeaGastrointestinal disorders1/430/961/139
DyspepsiaGastrointestinal disorders1/430/961/139
VomitingGastrointestinal disorders1/430/961/139
Lung disorderRespiratory, thoracic and mediastinal disorders1/430/961/139
Myocardial infarctionCardiac disorders1/430/961/139
NephrolithiasisRenal and urinary disorders1/430/961/139
Gastric ulcerGastrointestinal disorders0/431/961/139
Gastric volvulusGastrointestinal disorders0/431/961/139
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTCZ MONO - All ParticipantsTCZ COMBO - All ParticipantsTCZ - All Participants
Rheumatoid arthritisMusculoskeletal and connective tissue disorders8/4311/9619/139
BronchitisInfections and infestations7/439/9616/139
Ear infectionInfections and infestations5/433/968/139
RhinitisInfections and infestations2/4311/9613/139
AstheniaGeneral disorders1/439/9610/139
NasopharyngitisInfections and infestations4/438/9612/139
Urinary tract infectionInfections and infestations4/434/968/139
Back painMusculoskeletal and connective tissue disorders4/435/969/139
NauseaGastrointestinal disorders4/432/966/139
Injection site erythemaGeneral disorders4/433/967/139

Baseline characteristics

Full Analysis Set (FAS) included all participants who received at least one dose of SC TCZ.

Age, Continuous
Age, Continuous(years)TCZ - All Participants
Mean57.3 ± 13.8
Sex: Female, Male
Sex: Female, Male(Participants)TCZ - All Participants
Female103
Male36
08

Study locations

32 sites
  • Amiens, 80054, France
  • Bordeaux, 33076, France
  • Brest, 29609, France
  • Caen, 14033, France
  • Cahors, 46005, France
  • Clermont-ferrand, 63003, France
  • Echirolles, 38434, France
  • La Source, 45100, France
  • Le Mans, 72037, France
  • Lille, 59037, France
  • Limoges, 87042, France
  • Lomme, 59462, France
  • Lyon cedex 3, 69437, France
  • Marseille, 13274, France
  • Marseille, 13285, France
  • Metz Tessy, 74370, France
  • Monaco, 98012, France
  • Montpellier, 34295, France
  • Mulhouse, 68070, France
  • Paris, 75475, France
  • Paris, 75571, France
  • Paris, 75651, France
  • Paris, 75679, France
  • Paris, 75877, France
  • Rennes, 35033, France
  • Rouen, 76031, France
  • St Mande, 94163, France
  • St Priest En Jarez, 42277, France
  • Strasbourg, 67098, France
  • Thonon Les Bains, 74203, France
  • Toulouse, 31059, France
  • Vandoeuvre-les-nancy, 54511, France
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2013
First posted
Dec 5, 2013
Start
Jan 2014
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Nov 2, 2018
Last update
Nov 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02001987
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 5, 2013
Start date
Jan 2014
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Nov 2, 2018
Last update
Nov 2, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion